Prasugrels farmakokinetik er ens hos raske forsøgspersoner, patienter med stabil aterosklerose og patienter, som gennemgår perkutant koronarindgreb.
Prasugrel’ s pharmacokinetics are similar in healthy subjects, patients with stable atherosclerosis, and patients undergoing percutaneous coronary intervention.